Drug Trial Radar · NCT04777331
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
586
Actual
Start
May 5, 2021
Primary completion
Sep 11, 2024
Study completion Jun 30, 2031
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Prothena Biosciences Limited
- First posted
- Mar 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
Conditions
- Parkinsons Disease
Interventions
PrasinezumabDrug
Prasinezumab will be administered as an IV infusion to participants Q4W.
PlaceboDrug
Prasinezumab placebo will be administered to participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DBT Period: Time to Confirmed Motor Progression Event Assessed by Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IIITime frame: From study start to end of DBT period to at least 76 weeks
Locations
110 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Barrow Neurological Institute
Phoenix, Arizona
Neurology Center of North Orange County
Fullerton, California
UC San Diego
La Jolla, California
Keck School of Medicine of USC
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
University of California San Francisco
San Francisco, California
CenExel Rocky Mountain Clinical Research, LLC
Englewood, Colorado
Institute for Neurodegenerative Disorders
New Haven, Connecticut
JEM Research LLC
Atlantis, Florida
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Renstar Medical Research
Ocala, Florida
University of South Florida
Tampa, Florida
Charter Research - Winter Park/Orlando
Winter Park, Florida
Northwestern University Feinberg School Of Medicine
Chicago, Illinois
Southern Illinois University, School of Medicine
Springfield, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Quest Research Institute
Farmington Hills, Michigan
Henry Ford Hospital
West Bloomfield, Michigan
Dent Neurological Institute
Amherst, New York
Cleveland Clinic
Cleveland, Ohio
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma
University Pennsylvania Hospital
Philadelphia, Pennsylvania
Texas Neurology PA
Dallas, Texas
Baylor College of Medicine Medical Center
Houston, Texas
Central Texas Neurology Consultants
Round Rock, Texas
University of Vermont Medical Center
Burlington, Vermont
Sentara Neurology Specialists
Norfolk, Virginia
EvergreenHealth Investigational Drug Services
Kirkland, Washington
Inland Northwest Research
Spokane, Washington
Medizinische Universität Graz
Graz, Austria
Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck
Innsbruck, Austria
Klinik Ottakring
Vienna, Austria
Toronto Memory Program
Toronto, Ontario, Canada
Toronto Western Hospital
Toronto, Ontario, Canada
Clinique Neuro Outaouais
Gatineau, Quebec, Canada
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada
Groupe Hospitalier Pellegrin
Bordeaux, France
Groupement Hospitalier Est - Hôpital Neurologique
Bron, France
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.